HomeTrialNCT03651505
🔬NCT03651505ACTIVE NOT RECRUITING

X-linked Hypophosphatemia Disease Monitoring Program

Study Summary

The objectives of this observational study are to characterize XLH disease presentation and progression and to assess long-term effectiveness and safety of burosumab.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment782 participants
Primary Completion
Lead SponsorUltragenyx Pharmaceutical Inc
Data Retrieved2026-04-11 04:25:35.045796+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.